Understanding Asthma Treatment: BTS/SIGN Guidelines

Asthma is a chronic respiratory condition that affects millions of people worldwide. The British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) has developed a stepwise approach to managing asthma symptoms. The goal is to achieve complete control of symptoms while minimizing side effects from medication.

Step 1 involves using a short-acting beta-2 agonist (SABA) on an as-needed basis and a low-dose inhaled corticosteroid (ICS) regularly. If symptoms persist, step 2 involves adding a long-acting beta-2 agonist (LABA) to the ICS. Step 3 involves increasing the ICS dose or adding a leukotriene receptor antagonist (LTRA) if the LABA is ineffective. Step 4 involves increasing the ICS dose or adding a fourth medication, such as a slow-release theophylline or a long-acting muscarinic receptor antagonist (LAMA). Step 5 involves using a daily steroid tablet in the lowest effective dose while maintaining high-dose ICS and considering other treatments to minimize the use of steroid tablets.

It is important to note that the management of asthma in children under 5 years of age is different. Patients at step 4 or 5 should be referred for specialist care. Complete control of asthma symptoms is defined as no daytime or nighttime symptoms, no need for rescue medication, no asthma attacks, no limitations on activity, and normal lung function with minimal side effects from medication.

In summary, the BTS/SIGN guidelines provide a comprehensive approach to managing asthma symptoms. By following these guidelines, patients can achieve complete control of their symptoms while minimizing the risk of side effects from medication.

This patient is at a high risk of having a PE, scoring 7 points on her Wells’ score and presenting with a typical history of PE, along with several risk factors such as immobilisation and being on the COCP. Ideally, a CT pulmonary angiogram would be performed, but a contrast allergy is an absolute contraindication. Giving fluids or hydrocortisone and chlorphenamine would not reduce the risk of contrast allergy. A CT chest without contrast is not diagnostic for a PE. In such cases, a V/Q scan is the best option, but it may not be available out of hours. Therefore, given the strong suspicion of a PE, the patient should be started on treatment dose anticoagulation while awaiting the scan. NICE recommends using DOACs like apixaban as interim therapeutic anticoagulation. It is important to note that prophylactic heparin is used to prevent a PE, not to treat a PE.

Investigating Pulmonary Embolism: Key Features and Diagnostic Criteria

Pulmonary embolism (PE) can be challenging to diagnose as it can present with a wide range of cardiorespiratory symptoms and signs depending on its location and size. The PIOPED study in 2007 found that tachypnea, crackles, tachycardia, and fever were the most common clinical signs associated with PE. To aid in the diagnosis of PE, NICE updated their guidelines in 2020 to include the use of the pulmonary embolism rule-out criteria (PERC) and the 2-level PE Wells score. The PERC rule should be used when there is a low pre-test probability of PE, and a negative PERC result reduces the probability of PE to less than 2%. The 2-level PE Wells score should be performed if a PE is suspected, with a score of more than 4 points indicating a likely PE and a score of 4 points or less indicating an unlikely PE.

If a PE is likely, an immediate computed tomography pulmonary angiogram (CTPA) should be arranged, and interim therapeutic anticoagulation should be given if there is a delay in getting the CTPA. If a PE is unlikely, a D-dimer test should be arranged, and if positive, an immediate CTPA should be performed. The consensus view from the British Thoracic Society and NICE guidelines is that CTPA is the recommended initial lung-imaging modality for non-massive PE. However, V/Q scanning may be used initially if appropriate facilities exist, the chest x-ray is normal, and there is no significant symptomatic concurrent cardiopulmonary disease.

Other diagnostic tools include age-adjusted D-dimer levels, ECG, chest x-ray, V/Q scan, and CTPA. It is important to note that a chest x-ray is recommended for all patients to exclude other pathology, but it is typically normal in PE. While investigating PE, it is crucial to consider other differential diagnoses and to tailor the diagnostic approach to the individual patient’s clinical presentation and risk factors.

NICE guidelines recommend smoking cessation advice, annual influenza and one-off pneumococcal vaccinations, and pulmonary rehabilitation for COPD patients. Bronchodilator therapy is first-line treatment, with the addition of LABA and LAMA for patients without asthmatic features and LABA, ICS, and LAMA for those with asthmatic features. Theophylline is recommended after trials of bronchodilators or for patients who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients. Mucolytics should be considered for patients with a chronic productive cough. Loop diuretics and long-term oxygen therapy may be used for cor pulmonale. Smoking cessation and long-term oxygen therapy may improve survival in stable COPD patients. Lung volume reduction surgery may be considered in selected patients.

Understanding PEFR and Its Role in Diagnosing Asthma

Peak expiratory flow rate (PEFR) is a valuable tool in both the diagnosis and management of asthma. It is measured by a maximal forced expiration through a peak-flow meter and correlates well with forced expiratory volume in one second (FEV1), providing an estimate of airway calibre. Patients with asthma can monitor their PEFR at home to track disease control. A PEFR <80% of predicted is a strong indicator of obstructive airway disease, such as asthma. However, it’s important to note that PEFR is not affected by restrictive defects, such as those caused by kyphoscoliosis. Bronchial carcinoma itself does not cause airflow limitation, but a co-morbid obstructive lung disease, such as asthma or COPD, could produce abnormal PEFR readings. Bronchiectasis can cause an obstructive pattern on spirometry, but it would not typically cause a reduction in PEFR. Whooping cough, despite causing inflammation of the airways, would not typically result in the markedly reduced PEFR readings seen in asthma. In conclusion, understanding PEFR and its role in diagnosing asthma is crucial for both patients and healthcare providers. By monitoring PEFR at home and seeking medical attention when necessary, individuals with asthma can better manage their condition and improve their quality of life.

Causes of Pneumonia

Pneumonia is a respiratory infection that can be caused by various infectious agents. Community acquired pneumonia (CAP) is the most common type of pneumonia and is caused by different microorganisms. The most common cause of CAP is Streptococcus pneumoniae, which accounts for around 80% of cases. Other infectious agents that can cause CAP include Haemophilus influenzae, Staphylococcus aureus, atypical pneumonias caused by Mycoplasma pneumoniae, and viruses.

Klebsiella pneumoniae is another microorganism that can cause pneumonia, but it is typically found in alcoholics. Streptococcus pneumoniae, also known as pneumococcus, is the most common cause of community-acquired pneumonia. It is characterized by a rapid onset, high fever, pleuritic chest pain, and herpes labialis (cold sores).

In summary, pneumonia can be caused by various infectious agents, with Streptococcus pneumoniae being the most common cause of community-acquired pneumonia. It is important to identify the causative agent to provide appropriate treatment and prevent complications.

The most common causes of a mass in the anterior mediastinum are referred to as the 4 T’s: teratoma, terrible lymphadenopathy, thymic mass, and thyroid mass. The woman’s symptoms and positive anti-AChR suggest that she may have myasthenia gravis, which requires a CT chest to check for a thymoma. Other conditions that may show up on a CT chest, such as benign lung nodules, lung tumors, sarcoidosis, and tuberculosis, are unlikely given her presentation. It is important to note that the mediastinum is not the same as the lungs, and therefore, all other answer options are incorrect as the question specifically asks for an anterior mediastinal mass.

The Mediastinum and its Regions

The mediastinum is the area located between the two pulmonary cavities and is covered by the mediastinal pleura. It extends from the thoracic inlet at the top to the diaphragm at the bottom. The mediastinum is divided into four regions: the superior mediastinum, middle mediastinum, posterior mediastinum, and anterior mediastinum.

The superior mediastinum is located between the manubriosternal angle and T4/5 and contains important structures such as the superior vena cava, brachiocephalic veins, arch of aorta, thoracic duct, trachea, oesophagus, thymus, vagus nerve, left recurrent laryngeal nerve, and phrenic nerve.

The anterior mediastinum contains thymic remnants, lymph nodes, and fat. The middle mediastinum contains the pericardium, heart, aortic root, arch of azygos vein, and main bronchi. The posterior mediastinum contains the oesophagus, thoracic aorta, azygos vein, thoracic duct, vagus nerve, sympathetic nerve trunks, and splanchnic nerves.

In summary, the mediastinum is a crucial area of the chest that contains many important structures and is divided into four distinct regions.

Different Types of Lung Diseases and their Spirometry Patterns

Scoliosis and Lung Function
Severe scoliosis can affect the respiratory muscles and the natural movements of the thoracic cage, leading to a restrictive pattern in pulmonary function tests. This can prevent the lungs from expanding correctly, compromising their function.

Cystic Fibrosis and Lung Function
In early stage cystic fibrosis, the presence of inflammation and thick secretions in the airways can cause an obstructive pattern in spirometry tests. As damage to the lung tissue occurs, a restrictive component can also develop, resulting in a combined obstructive and restrictive pattern.

Emphysema and Lung Function
Emphysema is a type of obstructive lung disease characterized by abnormal and irreversible enlargement of air spaces and alveolar wall destruction. This leads to airflow limitation and a spirometry pattern typical of obstructive lung disease.

Asthma and Lung Function
Asthma is an inflammatory disorder of the airways that causes hyperresponsiveness and constriction of the airways in response to various stimuli. This leads to airflow limitation and a spirometry pattern typical of obstructive lung disease.

Bronchiectasis and Lung Function
Bronchiectasis is characterized by abnormal and irreversible dilatation of the bronchial walls, leading to accumulation of secretions and recurrent inflammation of the airways. This produces an obstructive pattern in pulmonary function tests.

In summary, different types of lung diseases can affect lung function in various ways, leading to different spirometry patterns. Understanding these patterns can help in the diagnosis and management of these conditions.

This presentation is characteristic of acute sickle chest syndrome.

Sickle cell anaemia is a condition that involves periods of good health with intermittent crises. There are several types of crises that can occur, including thrombotic or painful crises, sequestration, acute chest syndrome, aplastic, and haemolytic. Thrombotic crises, also known as painful crises or vaso-occlusive crises, are triggered by factors such as infection, dehydration, and deoxygenation. These crises are diagnosed clinically and can result in infarcts in various organs, including the bones, lungs, spleen, and brain.

Sequestration crises occur when sickling occurs within organs such as the spleen or lungs, leading to pooling of blood and worsening of anaemia. This type of crisis is associated with an increased reticulocyte count. Acute chest syndrome is caused by vaso-occlusion within the pulmonary microvasculature, resulting in infarction in the lung parenchyma. Symptoms include dyspnoea, chest pain, pulmonary infiltrates on chest x-ray, and low pO2. Management involves pain relief, respiratory support, antibiotics, and transfusion.

Aplastic crises are caused by infection with parvovirus and result in a sudden fall in haemoglobin. Bone marrow suppression leads to a reduced reticulocyte count. Haemolytic crises are rare and involve a fall in haemoglobin due to an increased rate of haemolysis. It is important to recognise and manage these crises promptly, as they can lead to serious complications and even death.

Differential Diagnosis of Polymyositis: A Comparison with Other Connective Tissue Diseases

Polymyositis is a systemic connective tissue disease that causes inflammation of the striated muscle and skin in the case of dermatomyositis. Patients typically present with muscle weakness, pain in the small joints of the fingers, and dermatitis. The disease is associated with HLA-B8 and HLA-DR3, and underlying malignancy is present in at least 5-8% of cases. Here, we compare polymyositis with other connective tissue diseases to aid in differential diagnosis.

Rheumatoid arthritis (RA) is another systemic inflammatory disease that affects mainly the joints, in particular, the proximal interphalangeal joints, in a symmetrical fashion. Pulmonary fibrosis is a known complication of RA, and muscular weakness is also a possible feature. However, in RA, joint-related symptoms are typically more prominent than muscle weakness, making polymyositis a more likely diagnosis in cases of predominant muscle weakness.

Cryptogenic fibrosing alveolitis, also known as idiopathic pulmonary fibrosis, presents with diffuse reticular infiltrates on chest radiographs and a restrictive pattern on lung function tests. However, the history of proximal muscle weakness and pain in the small joints of the hands does not fit with this diagnosis and suggests polymyositis instead.

Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects multiple systems in the body. While SLE would be in the differential diagnosis for polymyositis, the prominent proximal muscle weakness and the fact that the patient is a man (SLE affects women in 90% of cases) make polymyositis a more likely diagnosis.

Ankylosing spondylitis (AS) is an inflammatory rheumatic disease that primarily affects the axial joints and entheses. AS can be associated with pulmonary fibrosis and produces a restrictive pattern on spirometry. However, the more prominent complaint of proximal muscle weakness and the involvement of the small joints of the hands make AS a less likely diagnosis in cases of predominant muscle weakness.

The most frequent bacterial organism responsible for infective exacerbations of COPD is Haemophilus influenzae. This patient’s symptoms of dyspnoea, productive cough, and wheeze on a background of known COPD indicate an infective exacerbation. Nebulisers may be added to the treatment plan if the patient is significantly wheezy. Legionella pneumophila is not a common cause of COPD exacerbation, as it typically causes atypical pneumonia with desaturation on exertion and hyponatraemia. Moraxella catarrhalis is another organism that can cause infective exacerbations of COPD, but it is less common than Haemophilus influenzae. Staphylococcus aureus is the most common cause of pneumonia following influenza infection and can sometimes cause infective exacerbations of COPD, but it is not as common as Haemophilus influenzae.

Acute exacerbations of COPD are a common reason for hospital visits in developed countries. The most common causes of these exacerbations are bacterial infections, with Haemophilus influenzae being the most common culprit, followed by Streptococcus pneumoniae and Moraxella catarrhalis. Respiratory viruses also account for around 30% of exacerbations, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators such as salbutamol and ipratropium should also be administered, along with steroid therapy. IV hydrocortisone may be considered instead of oral prednisolone, and IV theophylline may be used for patients not responding to nebulized bronchodilators. Non-invasive ventilation may be used for patients with type 2 respiratory failure, with bilevel positive airway pressure being the typical method used.

Arterial Blood Gas Interpretation Made Easy

Arterial blood gas interpretation can be a daunting task for healthcare professionals. However, the Resuscitation Council (UK) has provided a simple 5-step approach to make it easier. The first step is to assess the patient’s overall condition. The second step is to determine if the patient is hypoxaemic, which is indicated by a PaO2 level of less than 10 kPa on air. The third step is to check if the patient is acidaemic or alkalaemic, which is determined by the pH level. A pH level of less than 7.35 indicates acidaemia, while a pH level of more than 7.45 indicates alkalaemia.

The fourth step is to assess the respiratory component by checking the PaCO2 level. A PaCO2 level of more than 6.0 kPa suggests respiratory acidosis, while a PaCO2 level of less than 4.7 kPa suggests respiratory alkalosis. The fifth and final step is to evaluate the metabolic component by checking the bicarbonate level or base excess. A bicarbonate level of less than 22 mmol/l or a base excess of less than -2mmol/l indicates metabolic acidosis, while a bicarbonate level of more than 26 mmol/l or a base excess of more than +2mmol/l indicates metabolic alkalosis.

To make it easier to remember, healthcare professionals can use the ROME acronym. Respiratory is opposite, which means that low pH and high PaCO2 indicate acidosis, while high pH and low PaCO2 indicate alkalosis. Metabolic is equal, which means that low pH and low bicarbonate indicate acidosis, while high pH and high bicarbonate indicate alkalosis. By following this simple approach, healthcare professionals can easily interpret arterial blood gas results and provide appropriate treatment for their patients.

The recommended treatment for acute pulmonary oedema in this patient is IV loop diuretic, specifically furosemide. This is because the patient is experiencing acute decompensated heart failure, which causes pulmonary oedema. IV loop diuretic has a prompt diuretic effect, reducing ventricular filling pressures and improving symptoms within 30 minutes.

IV dobutamine is not necessary for this patient as they are not in shock and dobutamine is typically reserved for patients with severe left ventricular dysfunction who have potentially reversible cardiogenic shock.

IV morphine is not recommended for acute heart failure as it may increase morbidity in patients with acute pulmonary oedema.

Oral furosemide is not the preferred route of administration for this patient as IV furosemide has a faster onset of diuresis.

Heart failure requires acute management, with recommended treatments for all patients including IV loop diuretics such as furosemide or bumetanide. Oxygen may also be necessary, with guidelines suggesting oxygen saturations be kept at 94-98%. Vasodilators such as nitrates should not be routinely given to all patients, but may have a role in cases of concomitant myocardial ischaemia, severe hypertension, or regurgitant aortic or mitral valve disease. However, hypotension is a major side-effect/contraindication. Patients with respiratory failure may require CPAP, while those with hypotension or cardiogenic shock may require inotropic agents like dobutamine or vasopressor agents like norepinephrine. Mechanical circulatory assistance such as intra-aortic balloon counterpulsation or ventricular assist devices may also be necessary. Regular medication for heart failure should be continued, with beta-blockers only stopped in certain circumstances. Opiates should not be routinely offered to patients with acute heart failure due to potential increased morbidity.

In summary, acute management of heart failure involves a range of treatments depending on the patient’s specific condition. It is important to carefully consider the potential side-effects and contraindications of each treatment, and to continue regular medication for heart failure where appropriate. Opiates should be used with caution, and only in cases where they are likely to reduce dyspnoea/distress without causing harm. With appropriate management, patients with acute heart failure can receive the care they need to improve their outcomes and quality of life.

Differentiating Types of Pneumonia: Causes and Characteristics

Pneumonia is a common respiratory infection that can be caused by various pathogens, including bacteria, viruses, and fungi. Among the bacterial causes, staphylococcal and pneumococcal pneumonia are two of the most prevalent types. However, they have distinct characteristics that can help clinicians differentiate them. In addition, other types of pneumonia, such as Pneumocystis jiroveci, Klebsiella, and fungal pneumonia, have specific risk factors and radiographic patterns that can aid in their diagnosis.

Staphylococcal pneumonia is often associated with a recent viral infection, intravenous drug use, or the presence of central lines. It typically presents as cavitating bronchopneumonia, which can be bilateral and complicated by pneumothorax, effusion, or empyema. Flucloxacillin is the drug of choice for treatment, although vancomycin can be used in penicillin-allergic patients.

Pneumococcal pneumonia, on the other hand, is more commonly acquired in the community and does not usually cause cavitating lesions. It can be suspected in patients with fever, cough, and chest pain, and is often treated with antibiotics such as penicillin or macrolides.

Pneumocystis jiroveci pneumonia is a type of fungal pneumonia that affects immunocompromised individuals, particularly those with HIV. It typically presents with an interstitial pattern on chest radiographs, rather than cavitating lesions.

Klebsiella pneumonia is another bacterial cause of cavitating pneumonia, often affecting elderly individuals or those with alcohol use disorders.

Fungal pneumonia, which can be caused by various fungi such as Aspergillus or Cryptococcus, tends to affect immunocompromised patients, but can also occur in healthy individuals exposed to contaminated environments. Its radiographic pattern can vary depending on the type of fungus involved.

In summary, understanding the different causes and characteristics of pneumonia can help clinicians make an accurate diagnosis and choose the appropriate treatment.

For an adult with asthma that is not controlled by a short-acting beta-agonist, the appropriate next step is to add a low-dose inhaled corticosteroid. This is in accordance with NICE guidelines. The addition of a combined inhaled corticosteroid and long-acting beta-agonist is not recommended until symptoms cannot be controlled with a low-dose inhaled corticosteroid and a short-acting beta-agonist, with or without a leukotriene receptor antagonist. Similarly, a leukotriene receptor antagonist or long-acting beta-agonist should not be introduced until symptoms are not controlled with a low-dose inhaled corticosteroid and a short-acting beta-agonist, with or without a leukotriene receptor antagonist.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

The patient’s history, examination, and obstructive spirometry results suggest that he has COPD, likely due to his smoking history. Malignancy has been ruled out by the chest x-ray. As per NICE guidelines, the first-line pharmacological treatment for COPD is either a SABA or SAMA to alleviate breathlessness and improve exercise tolerance. Ipratropium, a SAMA, is the most suitable option for this patient. Beclomethasone, an inhaled corticosteroid, is used as a second-line treatment with a LABA for those with asthmatic features or steroid responsiveness. Montelukast, a LTRA, is used as a third-line treatment in asthmatic patients, while Salmeterol, a LABA, is used as a second-line treatment in COPD patients.

NICE guidelines recommend smoking cessation advice, annual influenza and one-off pneumococcal vaccinations, and pulmonary rehabilitation for COPD patients. Bronchodilator therapy is first-line treatment, with the addition of LABA and LAMA for patients without asthmatic features and LABA, ICS, and LAMA for those with asthmatic features. Theophylline is recommended after trials of bronchodilators or for patients who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients. Mucolytics should be considered for patients with a chronic productive cough. Loop diuretics and long-term oxygen therapy may be used for cor pulmonale. Smoking cessation and long-term oxygen therapy may improve survival in stable COPD patients. Lung volume reduction surgery may be considered in selected patients.

Spirometry: The Best Diagnostic Tool for COPD

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition that can significantly impact a patient’s quality of life. To diagnose COPD, spirometry is the best diagnostic tool. According to NICE guidelines, a diagnosis of COPD should be made based on symptoms and signs, but supported by spirometry results. Post-bronchodilator spirometry should be performed to confirm the diagnosis. Airflow obstruction is confirmed by a forced expiratory volume in 1 s (FEV1):forced vital capacity (FVC) ratio of <0.7 and FEV1 <80% predicted. Other diagnostic tools, such as CT of the chest, serial peak flow readings, and trials of beclomethasone or salbutamol, may have a role in the management of COPD, but they are not used in the diagnosis of the condition. CT of the chest may be used to investigate symptoms that seem disproportionate to the spirometric impairment, to investigate abnormalities seen on a chest radiograph, or to assess suitability for surgery. Serial peak flow readings may be appropriate if there is some doubt about the diagnosis, in order to exclude asthma. Inhaled corticosteroids and short-acting beta agonists may be used in the management of COPD for breathlessness/exercise limitation, but they are not used in the diagnosis of COPD. In summary, spirometry is the best diagnostic tool for COPD, and other diagnostic tools may have a role in the management of the condition.

Correct and Incorrect Treatment Approaches for Acute Asthma Exacerbation in Children

Acute asthma exacerbation in children requires prompt and appropriate treatment to prevent complications. Here are some correct and incorrect treatment approaches for this condition:

Course of oral steroids: Giving oral steroids early in the treatment of acute asthma attacks in children is advisable. The initial course length should be tailored to response.

Wean down salbutamol to 2 puffs twice a day before hospital discharge: Weaning down salbutamol to two puffs twice a day before hospital discharge is incorrect. Children may be discharged from hospital once stable on 3- to 4-hourly bronchodilators which can be continued at home.

Addition of salmeterol inhaler: Adding a salmeterol inhaler is incorrect. The initial next step of treatment should be inhaled corticosteroids (ICSs) for patients who have had an asthma attack in the last two years.

Continue monitoring in hospital until salbutamol is no longer required: Continuing monitoring in hospital until salbutamol is no longer required is incorrect. Children may be discharged from hospital once stable on 3- to 4-hourly bronchodilators which can be continued at home.

IV hydrocortisone: Administering IV hydrocortisone is incorrect. It is reserved for the treatment of acute life-threatening asthma.

Identifying Bronchiectasis in a Patient with Cystic Fibrosis

Cystic Fibrosis (CF) is a genetic disorder that can lead to the development of bronchiectasis. Bronchiectasis is a condition characterized by dilated, thick-walled bronchi, which can result from continual or recurrent infection and inflammation caused by thick, difficult to expectorate mucus in patients with CF. In contrast, bronchiolitis is an acute lower respiratory infection that occurs in children aged <2 years, while asthma typically presents with variable wheeze, cough, breathlessness, and chest tightness. Chronic obstructive pulmonary disease (COPD) typically develops in smokers aged >40, and interstitial lung disease generally affects patients aged >45 and is associated with persistent breathlessness on exertion and cough. Therefore, in a patient with CF presenting with symptoms such as cough, breathlessness, and chest infections, bronchiectasis should be considered as a possible diagnosis.

Investigating and Diagnosing COPD

COPD is a condition that should be considered in patients over 35 years of age who are smokers or ex-smokers and have symptoms such as chronic cough, exertional breathlessness, or regular sputum production. To confirm a diagnosis of COPD, several investigations are recommended. These include post-bronchodilator spirometry to demonstrate airflow obstruction, a chest x-ray to exclude lung cancer and identify hyperinflation, bullae, or flat hemidiaphragm, a full blood count to exclude secondary polycythaemia, and a calculation of body mass index (BMI).

The severity of COPD is categorized based on the post-bronchodilator FEV1/FVC ratio. If the ratio is less than 70%, the patient is diagnosed with COPD. The severity of the condition is then determined based on the FEV1 value. Stage 1 is considered mild, and symptoms should be present to diagnose COPD in these patients. Stage 2 is moderate, Stage 3 is severe, and Stage 4 is very severe.

It is important to note that measuring peak expiratory flow is of limited value in COPD, as it may underestimate the degree of airflow obstruction. The grading system for COPD severity has changed following the 2010 NICE guidelines. If the FEV1 is greater than 80% predicted but the post-bronchodilator FEV1/FVC is less than 0.7, the patient is classified as Stage 1 – mild.

Psittacosis is a disease caused by the bacterium Chlamydia psittaci, which is typically transmitted to humans through exposure to infected birds. Symptoms include fever, cough, headache, and sore throat, as well as a characteristic facial rash. Diagnosis is confirmed through serology tests, and treatment involves the use of tetracyclines or macrolides. Mycoplasma pneumoniae is another bacterium that can cause atypical pneumonia, with symptoms including fever, malaise, myalgia, headache, and a rash. Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, while Legionella pneumophila can cause Legionnaires’ disease, which presents with fever, cough, dyspnea, and systemic symptoms. Coxiella burnetii is the bacterium responsible for Q fever, which can be transmitted by animals and arthropods and presents with non-specific symptoms. In the scenario presented, the patient’s history of exposure to infected birds and the presence of a rash suggest a diagnosis of psittacosis.